Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388726 · ClinicalTrials.gov registry record · Phase 3
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 762
- Enrollment target
NCT00388726: Completed Phase 3 study, sponsored by Eisai.
NCT00388726 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 762 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388726, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 762 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.
Primary Outcome
Defined as the time from the date of randomization until the date of death from any cause.
Interventions
- DRUG Physician's Choice
- DRUG E7389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 762 participants |
| Start Date | 2006-11 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT00388726 record still lists
NCT00388726 is an interventional study that assigns participants to a tested intervention. The registered 762 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Physician's Choice is the first listed.
NCT00388726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00388726 about?
NCT00388726 is a clinical study titled "E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer". The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast canc...
What is the current status of trial NCT00388726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 762 participants. The study started on 2006-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00388726?
The interventions under investigation include: Physician's Choice (DRUG), E7389 (DRUG).
Who is sponsoring clinical trial NCT00388726?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00388726's enrollment target sits among peer trials
762 449th of 2000 higher than 1,551 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06419374 · 762 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia